⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BIIB News
Biogen Inc. Common Stock
Microfluidics Market worth $37.2 billion by 2030 | MarketsandMarkets™
prnewswire.com
ABT
BDX
BIO
DHR
ILMN
PH
TMO
IDCC
FTV
BIIB
QDEL
HOG
SNIPES X SAUCONY® LAUNCH "CITY LIGHTS" COLLECTION: EXCLUSIVE FOOTWEAR COLORWAYS FUSING RUNNING HERITAGE WITH NEON-SOAKED STREET CULTURE
prnewswire.com
WMT
NKE
NDLS
ANF
ULTA
AZO
BBY
DLTR
ROST
TJX
URBN
M
KSS
LULU
ADSK
ADBE
GOOG
AMZN
MSFT
AAPL
FB
TSLA
NVDA
JPM
BAC
WFC
C
GS
MS
AXP
V
MA
DIS
CMCSA
VZ
T
SBUX
MCD
YUM
CMG
QSR
CBRL
PPC
KHC
PEP
KO
CL
PG
CLX
EL
UNP
CSX
NSC
CP
CNI
CAT
DE
BA
GD
LMT
RTX
HON
GE
MMM
XOM
CVX
SHEL
BABA
JD
PDD
NTES
BIDU
IQ
TAL
EDU
VIPS
ETSY
EBAY
WDC
HPQ
DELL
INTC
AMD
QCOM
MU
AMAT
LRCX
ADI
TXN
NXPI
MRVL
SNPS
CDNS
MCHP
ON
ALGN
ISRG
REGN
GILD
AMGN
BMY
PFE
JNJ
MRK
ABBV
LLY
NVS
AZN
XRAY
TMO
ILMN
EXAS
CRSP
VRTX
BIIB
IDXX
SWKS
CTAS
PAYX
ADP
CRM
NOW
INTU
FISV
PYPL
IFF
EMN
PPG
SHW
DD
DOW
LYB
ECL
RS
CF
MOS
NTR
ADM
BG
CARR
LILAK
CHTR
AVGO
GOOGL
META
Global Medical Radiation Detection Devices Market to Increase at a Steady Growth Rate of ~7% by 2032 | DelveInsight
globenewswire.com
VMI
SENS
HOG
GEHC
PHG
GM
TMO
PERI
MED
BIIB
Lupus Research Alliance Applauds U.S. FDA Breakthrough Therapy Designation for Litifilimab in Cutaneous Lupus Erythematosus
prnewswire.com
BIIB
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
globenewswire.com
BIIB
Boehringer Ingelheim und Simcere gehen Partnerschaft ein, um eine dual-zielgerichtete Antikörperbehandlung zur Behandlung von entzündlichen Darmerkrankungen voranzutreiben USA - Deutsch USA - English USA - English USA - Nederlands USA - Français
prnewswire.com
BIIB
App Test Automation Industry Research 2026 - Global Market Size, Share, Trends, Opportunities, and Forecasts, 2021-2025 & 2026-2031
globenewswire.com
LOGI
MSFT
GOOG
AMZN
IBM
ORCL
INTC
NVDA
CRM
ADBE
SAP
EA
TTWO
ROKU
NFLX
DIS
CMCSA
TCOM
MELI
SHOP
PYPL
UBER
LYFT
DDOG
PANW
CRWD
ZS
NOW
TWLO
SNOW
PLTR
AI
STX
WDC
HPQ
DELL
HPE
QCOM
MRVL
AMD
MU
AMAT
LRCX
KLAC
ASML
GLW
AVGO
NXPI
TER
KEYS
NI
CHKP
FTNT
PPC
LULU
SIRI
BBY
TJX
LOW
HD
CAT
BA
GD
LMT
RTX
HON
GE
MMM
AXP
JPM
BAC
WFC
C
GS
MS
V
MA
PG
KO
PEP
MCD
SBUX
VZ
T
CHTR
TMUS
AMGN
BMY
PFE
JNJ
MRK
ABBV
LLY
GILD
BIIB
REGN
VRTX
AZN
SNY
NVS
XOM
CVX
SHEL
BABA
JD
NTES
PDD
EDU
TAL
BIDU
VIPS
CPRT
Boehringer Ingelheim en Simcere werken samen aan een dubbeldoelgerichte antilichaambehandeling om tegemoet te komen aan onvervulde behoeften bij inflammatoire darmziekten USA - Nederlands USA - English USA - English USA - Français
prnewswire.com
BIIB
Boehringer Ingelheim et Simcere s'associent pour développer un traitement par anticorps à double cible afin de répondre aux besoins non satisfaits dans le domaine des maladies inflammatoires chroniques de l'intestin USA - Français USA - English USA -
prnewswire.com
BIIB
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease USA - English USA - English
prnewswire.com
BIIB